Skip to main content

Table 1 Characteristics of the included studies and outcome events

From: The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials

Study Countries Centers Publication Type of migraine Treatment group,
(No. of participants)
Total number Age range Female (%) Mean age ± SD (year) Study period Outcome Events
Goadsby et al
2020
(NCT02848326)
USA 78 Lancet Neurol episodic Atogepant 10 mg QD (93)
vs.30 mg QD (183)
vs.60 mg QD (186)
vs.30 mg BID (86)
vs.60 mg BID (91)
vs. PLA (186)
825 18y-75y 10 mg QD: 88
30 mg QD: 91
60 mg QD: 84
30 mg BID: 85
60 mg BID: 91
PLA: 83
10 mg QD:39.4 ± 12.4
30 mg QD:41.0 ± 13.6
60 mg QD:40.4 ± 11.7
30 mg BID:38.5 ± 11.2
60 mg BID:39.7 ± 11.9
PLA:40.5 ± 11.7
12w a b c d e
Ailani et al
2021
(NCT03777059)
USA 138 NEJM episodic Atogepant 10 mg QD (221)
vs.30 mg QD (228)
vs.60 mg QD (231)
vs. PLA (222)
902 18y-80y 10 mg QD: 90.5
30 mg QD: 89.5
60 mg QD: 86.1
PLA: 89.2
10 mg QD:41.1 ± 12.0
30 mg QD:42.1 ± 11.7
60 mg QD:42.5 ± 12.4
PLA: 40.3 ± 12.8
12w a b c d e
f g h
Allergan et al
2021
(NCT03700320)
USA 112 / episodic Atogepant 60 mg QD 739 18y-80y 60 mg QD: 88.2
PLA: 87.8
60 mg QD: 41.1 ± 12.1
PLA: 42.5 ± 12.03
52w a
  1. PLA placebo, w weeks a Adverse Events (AEs), b monthly migraine days (MMDs), c Monthly headache days, d Monthly medication use days, e ≥ 50% reduction in monthly migraine days, f Score on Role Function–Restrictive domain of MSQ, g Score on Performance of Daily Activities domain of AIM-D, h Score on Physical Impairment domain of AIM-D